Literature DB >> 23921710

Intracranial papillary meningioma: a clinicopathologic study of 30 cases at a single institution.

Xiao-Qiang Wang1, Hong Chen, Lin Zhao, Shi-Ting Li, Jie Hu, Guang-Hai Mei, Cheng-Chuan Jiang.   

Abstract

BACKGROUND: Papillary meningioma (PM) is an uncommon meningioma subtype, and the clinical characteristics remain unclear.
OBJECTIVE: To determine the clinical characteristics and prognosis of PM.
METHODS: The clinical data of 30 PM patients were collected, the samples were reexamined, and the patients' prognoses were based on clinical observations and calculated according to the Kaplan-Meier method.
RESULTS: The 30 patients included 16 males and 14 females (median: 34.0 years upon initial diagnosis). Of the 48 intracranial operations in the 30 patients, total removal was attained in 34 surgeries, and subtotal removal in 14 surgeries. Radiotherapy was provided in 20 patients. In 40 specimens with follow-up, 29 attained the positive aggressive factors. Six tumors showed positive progestogen receptor (PR) combined with negative Bcl-2. The median follow-up period was 39.0 months. Tumor recurrence occurred in 18 patients (median: 17.0 months); the recurrence rates following total removal and subtotal removal were 57.1% and 100%, respectively. Fourteen patients died of the recurrence. In the univariate analyses, positive aggressive factors (P = .021), positive PR combined with negative Bcl-2 immunoreactivity (P = .011), the extent of resection (P = .001), and radiotherapy (P = .002) were significantly related to progression-free survival. The MIB-1 labeling index was not significantly related to progression-free survival (P = .88).
CONCLUSION: PM is a rare subtype of meningioma with a tendency of recurrence. The extent of resection is an important prognosis factor. The presence of positive histopathological index increases the recurrence risk. Positive PR combined with negative Bcl-2 immunoreaction might predict a good prognosis. Postoperative radiotherapy may play a vital role in prolonging the time to tumor recurrence.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23921710     DOI: 10.1227/NEU.0000000000000133

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  5 in total

1.  Papillary meningioma of the central nervous system: a SEER database analysis.

Authors:  Fujun Liu; Yuan Tian; Liangxue Zhou
Journal:  Neurosurg Rev       Date:  2021-01-08       Impact factor: 3.042

2.  Papillary meningioma of the jugular foramen: A case report.

Authors:  Ying Yu; Haiyang Xu; Yubo Wang; Gang Zhao
Journal:  Oncol Lett       Date:  2015-10-08       Impact factor: 2.967

Review 3.  Pathology and molecular genetics of meningioma: recent advances.

Authors:  Makoto Shibuya
Journal:  Neurol Med Chir (Tokyo)       Date:  2014-12-20       Impact factor: 1.742

4.  Papillary meningioma with vital abnormal vessels.

Authors:  Hai-Bo Zhang; Yi-Ping Zhan; Xin-Guang Yu
Journal:  J Craniofac Surg       Date:  2014-07       Impact factor: 1.046

Review 5.  Intraventricular cystic papillary meningioma: A case report and literature review.

Authors:  Zhe Cheng; Qing Chao; Hui Zhang; Da-Wei Wang; Han-Sheng Shu
Journal:  Medicine (Baltimore)       Date:  2020-07-31       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.